Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase NA 1Phase 2 1Phase 1 1

Status

Unknown 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Melanoma 1

Interventions

Blood Specimen Collection 11Radiosurgery 7Sentinel Lymph Node Biopsy 5Early Intervention, Educational 5Surveys and Questionnaires 4Standard of Care 4Practice Guidelines as Topic 4Methods 4Indocyanine Green 4Educational Status 4X-Rays 3Surgical Procedures, Operative 3Nivolumab 3Magnetic Resonance Spectroscopy 3Ipilimumab 3Immunotherapy 3Cognitive Behavioral Therapy 3Biopsy 3pembrolizumab 2montanide ISA 51 2aldesleukin 2Tomography, X-Ray Computed 2Tomography, Emission-Computed 2Specimen Handling 2Radiotherapy 2Radiation 2Positron-Emission Tomography 2Palliative Care 2Observation 2Interviews as Topic 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase NA × Melanoma × oblimersen × Clear all
NCT00070343 2014-01-06

Oblimersen and Dacarbazine in Treating Patients With Advanced Malignant Melanoma That Has Responded to Treatment on Clinical Trial GENTA-GM301

National Cancer Institute (NCI)

Phase NA Unknown
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡